Market news

AstraZeneca's (AZN) $2 billion investment in Summit Therapeutics (SMMT) is a "win-win" and potential

SMMT shares jump as AstraZeneca commits $2 billion to accelerate ivonescimab development and expand clinical collaboration.

AstraZeneca buys $2 billion in Summit Therapeutics equity to test ivonescimab with ADCs, providing capital.

Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 26.8% to $0.32 during Tuesday's pre-market session. The company's market cap stands at $1.3 million. Summit Therapeutics (NASDAQ:SMMT) stock rose 16.34%

AstraZeneca invests $2 billion in Summit Therapeutics to combine cancer drugs ivonescimab and Sone-Ve.

Summit Therapeutics (NASDAQ:SMMT) shares rose 22% in pre-market trading on Tuesday after AstraZeneca (NASDAQ:AZN) agreed to make a $2 billion strategic equity investment in the biotechnology company. The investment will be made through newly issued convertible preferred shares at an effective common stock equivalent price of $18.

Sept 29 () - Summit Therapeutics' shares rose 23% in premarket trading on Tuesday after the drugmaker said AstraZeneca would invest $2 ‌billion in the company to test cancer treatments together. UK-listed shares ‌of AstraZeneca were up 1.

Stock futures inched lower in the premarket hours of Tuesday as market participants weighed a continued surge in government bond yields against persistent energ

Deals involving novel cancer therapies and weight-loss drugs reinforce the growing global appeal of Chinese biotech innovation.

AstraZeneca (LSE:AZN) shares rose 2. 0% on Tuesday after the pharmaceutical company announced a $2 billion strategic equity investment in Summit Therapeutics (NASDAQ:SMMT) alongside a clinical collaboration focused on cancer treatments.

AstraZeneca will put about $2 billion into Summit after the latter flagged in July that its cash pile was not enough to fund planned operations for a full year.

(Updates with recent stock movement in the headline and the first paragraph.) Summit Therapeutics

The deal would give AstraZeneca exposure to a promising cancer treatment without acquiring the company outright.

Investing.com -- Summit Therapeutics PLC (NASDAQ:SMMT) shares surged 15% in extended trading on Monday after pharmaceutical giant AstraZeneca PLC (NYSE:AZN) agreed to make a $2.0 billion strategic equity investment in the biopharmaceutical company. The substantial capital infusion underpins a multi-pronged collaboration designed to pair Summit’s flagship bispecific antibody, ivonescimab, with AstraZeneca’s extensive oncology pipeline.

Summit Therapeutics (SMMT) said late Monday AstraZeneca (AZN) has agreed to invest $2 billion in con

Tipranks Press Release.

Detailed price information for Summit Therapeu ADR (SMMT-Q) from The Globe and Mail including charting and trades.

Summit Therapeutics is rated Hold at $17.50 due to high uncertainty and insufficient conviction to take a position. Read more on SMMT stock here.

Ivonescimab beat Keytruda in a China Phase 3 NSCLC trial, cutting death risk 27% and extending survival.

Summit Therapeutics (NASDAQ:SMMT) shares rose 5. 8% in premarket trading on Wednesday after Jefferies upgraded the biopharmaceutical company to Buy from Hold and increased its price target to $25 from $15.

PARAMUS, N.J., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company employing standard-of-care therapies with proprietary delivery technologies, announced today that Chief Medical Officer, Dr. Jamie Oliver, PharmD., will present at the 17th Annual World Bispecific Summit held September 15-17, 2026, in Boston, MA. Details for the event are as follows: 17th Annual World Bispecific SummitLocation: The Westin Boston Seaport District, Boston

Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.

Summit Therapeutics Inc (SMMT) has an average rating of overweight and mean price target of $29.06,